Hypothesis: Emodin selectively induces apoptosis in EGFR‑high senescent pancreatic stellate cells by dual inhibition of EGFR‑STAT3 signaling and CDK2 activity

Rationale Emodin’s anti‑inflammatory profile stems from blockade of NF‑κB, JAK/STAT and MAPK cascades, yet it lacks proven senolytic activity1. In pancreatic cancer, emodin synergizes with afatinib to suppress compensatory STAT3 phosphorylation, revealing a latent ability to disrupt EGFR‑STAT3 survival loops2. Senescent pancreatic stellate cells (PSCs) in chronic pancreatitis and early pancreatic ductal adenocarcinoma overexpress EGFR and sustain STAT3‑driven SASP, making them dependent on the same axis that emodin attenuates in tumor cells.

Novel mechanistic insight Beyond EGFR‑STAT3, emerging data hint that emodin can bind the ATP‑pocket of CDK2, impairing its kinase activity and causing G1 arrest in cancer models3. CDK2 also phosphorylates and stabilizes the senescence‑associated transcription factor FOXM1, which promotes expression of anti‑apoptotic BCL‑XL in senescent cells. We propose that emodin’s simultaneous inhibition of EGFR‑STAT3 signaling and CDK2‑FOXM1‑BCL‑XL axis creates a synthetic lethal state uniquely in senescent PSCs that co‑overexpress EGFR and retain high CDK2 activity.

Testable predictions

1. In vitro: Treating irradiated human PSCs with emodin (10‑50 µM) will reduce viability >50 % only when EGFR phosphorylation is high (≥2‑fold over baseline) and CDK2 activity is detectable, as measured by phospho‑RB (Ser780). Senescent fibroblasts lacking EGFR overexpression will be resistant.
2. Molecular read‑outs: Emodin will decrease p‑STAT3 (Tyr705) and p‑ERK1/2, concurrently lowering CDK2‑mediated FOXM1 phosphorylation (Ser83) and BCL‑XL protein levels, leading to caspase‑3/7 activation. Rescue experiments with constitutively active STAT3 (STAT3‑C) or CDK2‑T160E mutant will blunt emodin‑induced death.
3. In vivo: In a murine model of chronic pancreatitis (cerulein‑induced), intra‑pancreatic delivery of emodin‑loaded nanoparticles will reduce p16^INK4a^+ PSC numbers by ~40 % without affecting α‑SMA^+ activated stellate cells, as quantified by immunofluorescence and flow cytometry. SASP cytokines (IL‑6, CXCL1) will drop proportionally.
4. Falsifiability: If emodin fails to kill EGFR‑high/CDK2‑active senescent PSCs under the above conditions, or if genetic ablation of EGFR or CDK2 does not phenocopy its effect, the hypothesis is refuted.

Implications Confirming this mechanism would reposition emodin from a broad anti‑inflammatory agent to a precision senolytic capable of targeting EGFR‑driven senescence in pancreatic pathology, offering a dual therapeutic window: attenuating inflammation while clearing pro‑tumorigenic senescent stromal cells.

References [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12985997/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6756157/ [3] https://pubmed.ncbi.nlm.nih.gov/39078513/